Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Market Cap | $786 | $892 | $1,291 | $1,734 |
| - Cash | $78 | $84 | $76 | $110 |
| + Debt | $56 | $52 | $27 | $28 |
| Enterprise Value | $764 | $859 | $1,242 | $1,652 |
| Revenue | $8 | $44 | $18 | $13 |
| % Growth | -82.1% | 138.7% | 38.9% | – |
| Gross Profit | $3 | -$34 | -$51 | -$54 |
| % Margin | 36.7% | -77.3% | -277.5% | -406.1% |
| EBITDA | -$81 | -$46 | -$61 | -$63 |
| % Margin | -1,031.4% | -104.6% | -327.9% | -477.3% |
| Net Income | -$86 | -$43 | -$56 | -$59 |
| % Margin | -1,094.8% | -98.7% | -305.4% | -440.7% |
| EPS Diluted | -1.03 | -0.52 | -0.67 | -0.75 |
| % Growth | -98.1% | 22.4% | 10.7% | – |
| Operating Cash Flow | -$57 | -$63 | -$61 | -$49 |
| Capital Expenditures | -$3 | -$3 | -$3 | -$2 |
| Free Cash Flow | -$60 | -$66 | -$65 | -$51 |